On Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript "Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma" was accepted for publication in the American Journal of Hematology.

The published study included a total of 168 smoldering multiple myeloma patients.

The article describes the results of Telo's prognostic test for smoldering multiple myeloma (TeloViewSMM).

The results described in the publication demonstrated superior performance characteristics compared to other oncology prognostic tests or scoring systems in smoldering multiple myeloma (SMM), particularly for SMM but also across other cancers.

In the published independent validation included in the study, the TeloView test scored an 85% positive predictive value (accuracy in identifying high-risk patients) and a 73% negative predictive value (accuracy in identifying stable patients), with associated sensitivity & specificity of 83% & 76%, respectively.

The test stratifies patients flagged with the elevated M-protein biomarker between high-risk patients who will progress to the full stage of myeloma disease and low-risk patients and confirms the stability of the disease in these patients.

Critically, TeloViewSMM can be used as a non-invasive liquid biopsy and can be performed using a simple blood draw.

According to recent demographic studies, SMM prevalence is estimated to be 0.5% of the population over 40 years old, suggesting that TeloViewSMM's total addressable market is approximately 500,000 tests and greater annually.

Earlier this month, Telo Genomics announced a non-brokered private placement of units at $0.25 per unit for gross proceeds of $2 million.

Price Action: TDSGF shares closed at $0.13 on Wednesday.